{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009526","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.756741+00:00","generated_at":"2026-06-01T00:59:15.273457+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coherus sells YUSIMRY (adalimumab-aqvh) to HKF for $40M upfront cash","bullets":["Upfront all-cash consideration of $40M; closing occurred June 26, 2024.","HKF's subsidiary Meitheal will commercialize YUSIMRY in the U.S.","HKF assumes $17M in inventory purchase commitments; Coherus retains certain excluded assets/liabilities.","Divestiture aligns with Coherus' strategic focus on oncology; proceeds to bolster cash position.","Coherus retains oncology assets including LOQTORZI, UDENYCA franchise, and immuno-oncology pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009526","json":"https://secwatch.observer/filing/0001558370-24-009526.json","markdown":"https://secwatch.observer/filing/0001558370-24-009526.md","text":"https://secwatch.observer/filing/0001558370-24-009526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/0001558370-24-009526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/chrs-20240626x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:59:15.273457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"886badad637fa0b09a1d6ac18c9a7277afe72c93","claim":"Coherus Oncology, Inc. completed a disposition involving Hong Kong King-Friend Industrial Company Ltd. for upfront, all-cash consideration of $40.0 million (closed 2024-06-26).","evidence_excerpt":"commitments, but not including certain identified excluded assets and excluded liabilities (collectively, the “YUSIMRY Disposition”) for upfront, all-cash consideration of $40.0 million paid on June 26, 2024. ​ The Purchase Agreement also provides for indemnification rights related to breaches of each party’s representations, warranties, covenants and certain","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/0001558370-24-009526-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Hong Kong King-Friend Industrial Company Ltd."},{"label":"Consideration","value":"upfront, all-cash consideration of $40.0 million"},{"label":"Closing","value":"2024-06-26"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}